


**JACIE**

**Common Non-Compliances 5th Edition**


**Based on presentation by Carole Charley,  
JACIE Report Assessor, at EBMT 2016 Valencia**


- 87% (146/168) of reports based on the 5<sup>th</sup> Edition have been analysed

Distribution of total items from reports



Distribution of total items from reports showing full/partial deficiencies





## B03: PERSONEL

### ❖ 103 Standards





## **B03: PERSONEL : Education**

Over 60<sup>+</sup>/103 standards

Lack of evidence for:

X Attending physicians participate in educational activities

X Mid level practitioners participation


X Training in donor evaluation & management

X Nurses formally trained & experienced

?

# B03/B04: PERSONNEL Education

- QMP



X Continued competency at least annually.

Across all facilities



## D04 Quality Management

### Lack of evidence

#### Processing

D04.14.1 (15) *Critical procedures to be validated or verified shall include at least the following processing techniques, cryopreservation procedures, labeling, storage, and distribution.*

D.04 (10) *The Quality Management Plan shall include, or summarize and reference, policies and procedures for establishment and maintenance of written agreements with third parties whose services impact the cellular therapy product.*

**X** Agreements shall be dated, reviewed, and renewed on a regular basis.





# C04/D04 Quality Management

## Quality Management

### Plan

#### Collection

- - X Should describe the minimal trainer qualification and a uniform plan of staff training

- X Should include or summarize the procedure to implement policies

#### Collection & Processing

- X Should include maintenance of written agreements and to include all responsibilities and reviewed on a regular basis

- Number of standards: B=71/CM=2/C=76/D=81



## B04 Quality Management

**X Review of outcome analysis and product efficacy shall include at a Minimum**

### Clinical

**X For HPC products, overall and treatment-related morbidity and mortality at 100 days and 1 year after transplantation.**

**X For other cellular therapy products, the criteria for product efficacy and/or the clinical outcome shall be determined and shall be reviewed at regular time intervals.**



## C0/D04 Quality Management

**X Review of outcome analysis and product efficacy shall include at a Minimum**

### Processing D4.07

- X A process for documentation of engraftment**
- X Other products efficiency**



B4/C4/D4

## QUALITY MANAGEMENT

### CLINICAL

**X** The clinical Program Director or designee shall report on quality management activities, at a minimum, quarterly

B4/C4/D4



## QUALITY MANAGEMENT

### The Clinical Program

shall periodically audit at a minimum

- X Accuracy of MEDA DATA
- X Verification of chemotherapy drug and dose against the orders and the protocol
- X Collection and analysis of data related to the audit shall be reviewed, reported, and documented, at a minimum, on an annual basis









## The Collection & Processing facilities shall periodically audit at a minimum:

- Collection

X Documentation that external facilities meet the written agreements

- Processing (16)

X Audits shall include documentation that external facilities performing critical contracted services have met the requirements of the written agreements

 W1582 03 0663508 <b>G</b>		 8400	<b>A Rh Positive</b>
<b>Collection Date</b>  0031122359 <b>22 APR 2003</b> <small>Preserve, do not intend to be used and/or used This product may be used in infectious agents R only See Circular of Information for the Use of Cellular Therapy Products</small>	<b>FOR AUTOLOGOUS USE ONLY</b> <b>DO NOT IRRADIATE</b> <b>DO NOT USE LEUKOREDUCTION FILTER</b>		
 S0009100    AUTOLOGOUS	 0031122359 <b>22 APR 2003</b>	<b>Expiration Date</b>	
<b>CRYOPRESERVED HPC, APHERESIS</b>	 122222	<b>CMV NEGATIVE</b>	
<small>Collected and Processed by HPC Center Anywhere, Worldwide</small>			

## Processing

- ✗ Each label shall bear the information in the Cellular Therapy Product Labeling Table in Appendix I codes
- ✗ Misuse of biohazard labels

## C07/D07: LABELLING

### Collection & Processing

- ✗ Use of ISBT 128 labelling and codes
- ✗ Plan to implement plan for ISBT 128

New EU Regulations:  
Single Euro Coding system



# OVERVIEW

	Clinical	Collection	Processing
Personnel	X		
QMS	X	X	X
Process control			X
Labeling		X	X
Records			X
Product Storage			X
Transport & Shipping			X



## Challenge of working with a QMS: Evidence

- Effective documentary evidence that each standard is compliant
  - Complete training and competencies records
  - QMP to describe all processes
  - QMS to carry out processes described in QMP
  - Carry out all audits required including external audits & follow up of corrective measure
  - Document outcome analysis
  - Agreements to include responsibilities

